机构：[a]School of Life Sciences and Technology, Tongji University, Shanghai, China[b]College of Medicine, Henan University of Science and Technology, Luoyang, Henan, China[c]Shanghai Tongji Hospital, Tongji University, Shanghai, China[d]Biomedical Research Center, Tongji University Suzhou Institute, Suzhou, Jiangsu, China[e]Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院
Since tumors are often infiltrated by macrophages, it would be advantageous to turn these types of cells into cytotoxic effector cells. Here, we have designed a novel bispecific antibody (BsAb) that targets both tumor antigen (CD20) and the FcαRI receptor (CD89). This antibody could be used to lyse tumors by connecting tumor cells to CD89-expressing immune effector cells such as macrophages and neutrophils. Previously there were very limited attempts to exploit FcαRI-expressing cells as effector cells for tumor cell-killing, largely due to the lack of an appropriate in vivo model, since mice do not express a human CD89 homolog. In this study, we used a transgenic mouse strain with specific expression of CD89 on macrophages and monocytes. In this transgenic mouse model, the CD89 bispecific antibody showed significant anti-tumor activities, demonstrating that bispecific antibodies can redirect macrophages, including M2 macrophages, to mediate additional effector function in the tumor microenvironment. This approach realized the full potential of the innate immune system and could be applied to other tumor-associated antigens especially the solid tumors, thus has potential to translate into clinical benefits in human cancers.
基金：
This study was supported by grants from the National
Natural Science Foundation of China (NSFC31270987, NSFC31470896,
and NSFC81402399), National Basic Research Program of China (973 Program)
2015CB553706.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|1 区医学
小类|2 区免疫学2 区肿瘤学
最新[2023]版：
大类|2 区医学
小类|2 区免疫学2 区肿瘤学
第一作者：
第一作者机构：[a]School of Life Sciences and Technology, Tongji University, Shanghai, China
共同第一作者：
通讯作者：
通讯机构：[a]School of Life Sciences and Technology, Tongji University, Shanghai, China[c]Shanghai Tongji Hospital, Tongji University, Shanghai, China[d]Biomedical Research Center, Tongji University Suzhou Institute, Suzhou, Jiangsu, China[e]Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China[*1]School of Life Sciences and Technology, Tongji University, 1239 Siping Road, Shanghai, China 200092.
推荐引用方式(GB/T 7714)：
Bingyu Li,Lijun Xu,Chenyu Pi,et al.CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.[J].Oncoimmunology.2017,7(1):e1380142.doi:10.1080/2162402X.2017.1380142.
APA：
Bingyu Li,Lijun Xu,Chenyu Pi,Yanxin Yin,Kun Xie...&Jianmin Fang.(2017).CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy..Oncoimmunology,7,(1)
MLA：
Bingyu Li,et al."CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.".Oncoimmunology 7..1(2017):e1380142
医学